Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2002-07-08
2010-06-29
Schnizer, Richard (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500
Reexamination Certificate
active
07745420
ABSTRACT:
The invention relates to the use of nucleotide substitutes for increasing the in vivo efficacy of nucleic acid molecules and also for inhibiting inflammation in mammals. More particularly, the present invention relates to the use of 2′6′diaminopurine (DAP) and analogs thereof per se in anti-inflammatory compositions, and also for preparing nucleic acid molecules having an increased in vivo physiological efficiency and a reduced toxicity as compared to conventional oligos. The invention is particularly useful for the preparation of antisense oligonucleotides for treating pulmonary/respiratory diseases such as cystic fibrosis, asthma, chronic bronchitis, chronic obstructive lung disease, eosinophilic bronchitis, allergies, allergic rhinitis, pulmonary fibrosis, adult respiratory distress syndrome, sinusitis, respiratory syncytial virus or other viral respiratory tract infection and cancer.
REFERENCES:
patent: 3337530 (1967-08-01), Hanze
patent: 5523205 (1996-06-01), Cossart et al.
patent: 5856466 (1999-01-01), Guinosso et al.
patent: 5925624 (1999-07-01), Gregson et al.
patent: 6175004 (2001-01-01), Ross et al.
patent: WO 99/02732 (1999-01-01), None
patent: WO 99/66037 (1999-12-01), None
patent: WO 99 66037 (1999-12-01), None
patent: WO 99 67378 (1999-12-01), None
patent: WO 00/09525 (2000-02-01), None
patent: WO 00 12563 (2000-03-01), None
patent: WO 00/62736 (2000-10-01), None
Buhr et al (Nucl. Acids. Res. 24(15): 2974-2980, 1996).
Le Moine et al (Journal of Immunology, 156(11): 4408-14, 1996).
Marak et al (Opthalmic Res. 20(4): 220-226, 1988).
Crooke S T: “Basic Principles of Antisense Therapeutics” Antisense Research and Applications, CRC Press, GB, 1998, pp. 1-50, XP000900999 p. 12, pp. 22-26, table 1, pp. 33-36.
Sanghvi Y S: “Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides” Antisense Research and Applications, CRC Press, GB, 1993, pp. 273-288, XP002921486 pp. 274 (introduction), p. 280, figure 3, compounds 34, 39, 41, 49a.
Uhlmann E et al: “Antisense Oligonucleotides a New Therapeutic Principle” Chemical Reviews, American Chemical Society. Easton, US, vol. 90, No. 4, Jun. 1, 1990, pp. 543-584, XP000141412 ISSN 0009-2665 pp. 556-557, figure 33, pp. 573-574.
Balow G et al: “Biophysical and antisense properties of oligodeoxynucleotides containing 7-propenyl-, 7-iodo- and 7-cyano-7-deaza-2-amino-2′deoxya denosines” Nucleic Acids Research, Oxford University Press, Surrey, GB, vol. 26, No. 14, 1998, pp. 3350-3357, XP002157793 ISSN: 0305-1048 p. 3355 last paragraph, p. 3356 first paragraph.
A.R. Hanze: “Nucleic acids. V. Nucleotide Derivatives of Tubercidin (7-Deazaadenosine)” Biochemistry, vol. 7, No. 3, 1968; pp. 932-939, XP002224917 Compounds XII and XIII, Figure 2; p. 934.
J. Santalucia, R. Kierzek, D.H. Turner: “Functional Group Substitutions as Probes of Hydrogen Bonding between GA Mismatches in RNA Internal Loops” Journal of the American Chemical Society, vol. 113, 1991, pp. 4313-4322, XP002224918 p. 4314, 2A mismatch, Tables, examples.
R. Saladino, E. Mincione, C. Crestini, N. Mezzetti: “Transformations of thiopyrimidine and thiopurine nucleosides following oxidation with dimethyldioxirane” Tetrahedron, vol. 52, No. 19, 1996, pp. 6759-6780, XP002224919 compound 24b p. 6765-p. 6767.
Nandanan E. el al: “Structure-activity relationships of bisphosphate nucleotide derivatives as P2Y1 receptor antagonists and partial agonists” Journal of Medicinal Chemistry, vol. 42, 1999, pp. 1625-1638, XP002224920 p. 1627, compounds 29a and 29b.
S. Ali el al: “Absorption, distribution, metabolism and excretion of a respirable antisense oligonucleotide for asthma” American Journal of Respiratory and Critical Care Medicine, vol. 163, 2001, pp. 989-993, XP002224921 cited in the application, the whole document.
Ortoleva-Donnelly, Lori et al., RNA; 4:498-519 (1998).
Strauss-Soukup, Juliane K. et al.; J. Mol. Biol. 302:339-358 (2000).
Strobel, Scott A. et al.; Proc. Natl. Acad. Sci. USA; 94:2903-2908 (Apr. 1997).
Crooke, S.T., “Progress in Antisense Therapeutics”, Hematologic Pathology, 9(2), 59-72 (1995).
Cheng, X., “Structure and Function of DNA Methyltransferases”, Annu. Rev. Biophys. Biomol. Struct., 24:293-318, (1995).
Khudyakov, I. Ya., et al., “Cyanophage S-2L Contains DNA With 2,6-Diaminopurine Substituted for Adenine”, Virology 88, 8-18 (1978).
Balzarini, Jan, et al., “The 2′,3′-Dideoxyriboside of 2,6-Diaminopurine Selectively Inhibits Human Immunodeficiency Virus (HIV) Replication in Vitro ”, Biochemical and Biophysical Research Communications, vol. 145, No. 1, pp. 269-276, (1987).
Rackwitz, H.R. et al., “The Stereochemical Basis of Template Function”, Eur. J. Biochem, 72, 191-200, (1977).
Templin, M.V. et al., “Pharmacokinetic and Toxicity Profile of a Phosphorothioate Oligonucleotide Following Inhalation Delivery to Lung in Mice”, Antisense and Nucleic Acid Drug Development 10:359-368, (2000).
Ali, S. et al., “Absorption, Distribution, Metabolism, and Excretion of a Respirable Antisense Oligonucleotide for Asthma”, American Journal Respir Crit Care Med, vol. 163, pp. 989-993, (2001).
Chollett, A. et al., “DNA containing the base analogue 2-aminoadenine: preparation, use as hybridization probes and cleavage by restriction endonucleases”, Nucleic Acids Research, vol. 16, No. 1, pp. 305-317 (1988).
Bailly, C. et al., “Transferring the purine 2-amino group from guanines to adenines in DNA changes the sequence-specific binding of antibiotics”, Nucleic Acids Research, vol. 23, No. 6, pp. 885-892, (1995).
Bailly, C. et al., “PCR-based development of DNA substrates containing modified bases: An efficient system for investigating the role of the exocyclic groups in chemical and structural recognition by minor groove binding drugs and proteins”, Proc. Natl. Acad. Sci. USA, vol. 93, pp. 13623-13628, Nov. 1996.
Hoheisel, J.D. et al., “Quantitative measurements on the duplex stability of 2,6-diaminopurine and 5-chloro-uracil nucleotides using enzymatically synthesized oligomers”, Federation of European Biochemical Societies, vol. 274, No. 1,2, pp. 103-106, Nov. 1990.
Renzi, P.M. et al., “Effect of Interleukin-2 on the Airway Response to Antigen in the Rat1-4”, Am Rev Respir Dis 146:163-169, (1992).
Mann, J.S. et al., “Airway effects of purine nucleosides and nucleotides and release with bronchial provocation in asthma”, J. Appl. Physiol. 61:1667-1676, (1986).
Tanaka, M. et al., “Respirable antisense oligonucleotides: a new drug class for respiratory disease”, Respiratory Research 2:5-9, (2001).
Dias, N. et al., “Antisense Oligonucleotides: Basic Concepts and Mechanisms”, Molecular Cancer Therapeutics, vol. 1, pp. 347-355, Mar. 2002.
Gauvreau, G.M. et al., “Antisense Therapy against CCR3 and the Common Beta Chain Attenuates Allergen-induced Eosinophilic Responses”, Am J Respir Crit Care Med, vol. 177, pp. 952-958, (2008).
Allakhverdi Zoulfia
Allam Mustapha
Renzi Paolo
Nixon & Peabody LLP
Schnizer Richard
Topigen Pharmaceutique Inc.
Townes Jeffrey N.
LandOfFree
Methods for increasing in vivo efficacy of oligonucleotides... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for increasing in vivo efficacy of oligonucleotides..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for increasing in vivo efficacy of oligonucleotides... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4206412